Jubilant Pharmova’s US Unit Clears USFDA PADE Inspection with Zero Observations

Jubilant Pharmova Limited announced a major regulatory milestone as its subsidiary, Jubilant Cadista Pharmaceuticals Inc. (USA), successfully passed a USFDA Post-marketing Adverse Drug Experience (PADE) inspection on September 19, 2025, with zero observations. The flawless outcome underscores the company’s robust pharmacovigilance systems and commitment to quality, safety, and regulatory compliance in the highly scrutinized pharmaceutical sector. Jubilant Cadista is part of Jubilant Pharma Limited, a wholly-owned subsidiary of Jubilant Pharmova. The parent company operates globally across key segments including radiopharma, allergy immunotherapy, CDMO, CRDMO, and generics, serving as a trusted partner to leading pharma firms. With 45 radiopharmacies in the US and R&D centers in India and France, Jubilant Pharmova continues to strengthen its reputation as a 'Partner of Choice' in global healthcare. This clean chit from the USFDA reinforces its leadership in drug safety and quality assurance.